Skip to main content
SpringerLink
Log in

Treatment of Systemic Sclerosis

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Systemic sclerosis is an extremely variable disease in its manifestations and consequently, treatment needs to be individualized depending on the specific problems that each patient has. Limited scleroderma patients have a prolonged duration of Raynaud’s phenomenon and puffy fingers before they develop any skin thickening, digital ulcers or gastrointestinal symptoms. They are likely to present with all the classic manifestations of scleroderma. Diffuse scleroderma patients have a much more acute systemic onset with marked whole hand swelling and may initially have only subtle skin thickening. A good understanding of the differences between the natural history of limited and diffuse scleroderma will enable the physician to treat present problems and anticipate future ones more effectively. One should determine which major subset and organ systems are involved before deciding on the appropriate therapy. Advances in organ-specific therapy, particularly calcium channel antagonists in Raynaud’s phenomenon, proton pump inhibitors in esophageal reflux, intravenous iloprost and endothelin receptor antagonists in pulmonary hypertension, and ACE inhibitors in renal crisis, have decreased morbidity and mortality in patients with scleroderma. Studies of aggressive therapies to prevent or improve pulmonary fibrosis are in progress. Further clinical experience in wound healing, gastrointestinal malabsorption and physical therapy for loss of motion has helped patients to have a more comfortable life. In recent years, a significant number of controlled clinical trials have been performed and there has been improved understanding of the best way to perform studies and of which patients are most likely to respond to therapy. Penicillamine, methotrexate, photopheresis, relaxin, interferons, and cyclosporine have all been studied in controlled trials with variable outcomes. Although an overall remittive therapy has not yet been determined, new, potentially useful agents are being investigated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Weide B., Walz T., Garbe C. Is morphoea caused by Borrelia Burgdorferi? a review. Br J Dermatol 2000; 142 (4): 636–644

    Article  PubMed  CAS  Google Scholar 

  2. Strehlow D., Korn J.H. Biology of the scleroderma fibroblast. Curr Opin Rheumatol 1998; 10 (6): 572–578

    Article  PubMed  CAS  Google Scholar 

  3. Arnett F.C., Tan F.K., Uziel Y., et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin 1, in patients with localized scleroderma. Arthritis Rheum 1999; 42 (12): 2656–659

    Article  PubMed  CAS  Google Scholar 

  4. Arnett F.C. HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol 1995; 12 (2-4): 107–128

    Article  PubMed  CAS  Google Scholar 

  5. Steen V.D., Medsger Jr T.A.. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43 (11): 2437–2444

    Article  PubMed  CAS  Google Scholar 

  6. Steen V.D., Powell D.L., Medsger Jr T.A. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31 (2): 196–203

    Article  PubMed  CAS  Google Scholar 

  7. Okano Y., Steen V.D., Medsger Jr T.A. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993 Nov 15; 119 (10): 1005–1013

    PubMed  CAS  Google Scholar 

  8. Wigley F.M., Wise R.A., Seibold J.R., et al. Intravenous iloprost infusion in patients with raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebocontrolled, double-blind study. Ann Intern Med 1994 Feb 1; 120 (3): 199–206

    PubMed  CAS  Google Scholar 

  9. Vivino F.B., Al Hashimi I., Khan Z., et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999 Jan 25; 159 (2): 174–181

    Article  PubMed  CAS  Google Scholar 

  10. Iwabuchi Y., Masuhara T. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjorgen’s syndrome. Gen Pharmacol 1994; 25 (1): 123–129

    Article  PubMed  CAS  Google Scholar 

  11. Descamps V., Duval X., Crickx B. Global improvement of systemic scleroderma under long-term administration of octreotide. Eur J Dermatol 1999; 9 (6): 446–448

    PubMed  CAS  Google Scholar 

  12. Silver R.M., Warrick J.H., Kinsella M.B., et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20 (5): 838–844

    PubMed  CAS  Google Scholar 

  13. White B., Moore W.C., Wigley F.M., et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000 Jun 20; 132 (12): 947–954

    PubMed  CAS  Google Scholar 

  14. Klings E.S., HillN S., Ieong M.H., et al. Systemic sclerosis-associated pulmonary hypertension: short- and long- term effects of epoprostenol (prostacyclin). Arthritis Rheum 1999; 42 (12): 2638–2645

    Article  PubMed  CAS  Google Scholar 

  15. Channick R.N., Rubin L.J., Bodin F., et al. Bosentan, a dual endothelin receptor antagonist, improves exercise capacity and hemodynamics in patients with pulmonary arterial hypertension: results of a double blind, randomized, placebo-controlled trial [abstract no. 476]. Circulation 2000; 102 (18): 476

    Google Scholar 

  16. Steen V.D., Medsger Jr T.A. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000; 17: 600–603

    Google Scholar 

  17. Dziadzio M., Denton C.P., Smith R., et al. Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999; 42 (12): 2646–2655

    Article  PubMed  CAS  Google Scholar 

  18. Biasi D., Carletto A., Caramaschi P., et al. Iloprost as cyclic five-day infusions in the treatment of scleroderma: an open pilot study in 20 patients treated for one year. Rev Rhum Engl Ed 1998; 65 (12): 745–750

    PubMed  CAS  Google Scholar 

  19. Wigley F.M., Korn J.H., Csuka M.E., et al. Oral iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, placebocontrolled, double-blind study. Arthritis Rheum 1998; 41 (4): 670–677

    Article  PubMed  CAS  Google Scholar 

  20. Pope J., Fenlon D., Thompson A., et al. Ketanserin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Systematic Reviews. Available in the Cochrane Library [database on disk and CD Rom]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Oxford Update Software, 2000: CD000954

    Google Scholar 

  21. Pope J., Fenlon D., Thompson A., et al. Prazosin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Systematic Reviews. Available in the Cochrane Library [database on disk and CD Rom]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Oxford Update Software, 2000: CD000956

    Google Scholar 

  22. Pope J., Fenlon D., Thompson A., et al. Cyclofenil for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Systematic Reviews. Available in the Cochrane Library [database on disk and CD Rom]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Oxford Update Software, 2000: CD000955

    Google Scholar 

  23. Isner J.M., Baumgartner I., Rauh G., et al. Treatment of thromboangiitis obliterans (Buerger’s Disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 1998; 28 (6): 964–973

    Article  PubMed  CAS  Google Scholar 

  24. Bunker C.B., Reavley C., O’shaughnessy D.J., et al. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud’s phenomenon. Lancet 1993 Jul 10; 342 (8863): 80–83

    Article  PubMed  CAS  Google Scholar 

  25. Herrick A.L., Hollis S., Schofield D., et al. A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 2000; 18 (3): 349–356

    PubMed  CAS  Google Scholar 

  26. Destors J.M., Gauthier E., Lelong S., et al. Failure of a pure anti-platelet drug to decrease the number of attacks more than placebo in patients with Raynaud’s phenomenon. Angiology 1986; 37 (8): 565–569

    Article  PubMed  CAS  Google Scholar 

  27. Falanga V., Fujitani R.M., Diaz C., et al. Systemic treatment of venous leg ulcers with high doses of pentoxifylline: efficacy in a randomized, placebo-controlled trial. Wound Repair Regen 1999; 7 (4): 208–213

    Article  PubMed  CAS  Google Scholar 

  28. Franks A.G. Topical glyceryl trinitrate as adjunctive treatment in Raynaud’s disease. Lancet 1982 Jan 9; I (8263): 76–77

    Article  Google Scholar 

  29. Teh L.S., Manning J., Moore T., et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenon. Br J Rheumatol 1995; 34 (7): 636–641

    Article  PubMed  CAS  Google Scholar 

  30. Tucker A.T., Pearson R.M., Cooke E.D., et al. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud’s syndrome: a randomised trial. Lancet 1999 Nov 13; 354 (9191): 1670–1675

    Article  PubMed  CAS  Google Scholar 

  31. Ward W.A., Van Moore A. Management of finger ulcers in scleroderma. J Hand Surg [Am] 1995; 20 (5): 868–872

    Article  CAS  Google Scholar 

  32. Melone Jr C.P., McLoughlin J.C., Beldner S. Surgical management of the hand in scleroderma. Curr Opin Rheumatol 1999; 11 (6): 514–520

    Article  PubMed  Google Scholar 

  33. Yee A.M., Hotchkiss R.N., Paget S.A. Adventitial stripping: a digit saving procedure in refractory Raynaud’s phenomenon. J Rheumatol 1998; 25 (2): 269–276

    PubMed  CAS  Google Scholar 

  34. Dutz J. Treatment options for localized scleroderma. Skin Therapy Lett 2000; 5 (2): 3–5

    PubMed  CAS  Google Scholar 

  35. Palmieri G.M., Sebes J.I., Aelion J.A., et al. Treatment of calcinosis with diltiazem. Arthritis Rheum 1995; 38 (11): 1646–1654

    Article  PubMed  CAS  Google Scholar 

  36. Vayssairat M., Hidouche D., Abdoucheli-Baudot N., et al. Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis: does diltiazem induce its regression? Ann Rheum Dis 1998; 57 (4): 252–254

    Article  PubMed  CAS  Google Scholar 

  37. Bottomley W.W., Goodfield M.J., et al. Digital calcification in systemic sclerosis: effective treatment with good tissue preservation using the carbon dioxide laser. Br J Dermatol 1996; 135 (2): 302–304

    Article  PubMed  CAS  Google Scholar 

  38. Nalebuff E.A. Surgery in patients with systemic sclerosis of the hand. Clin Orthop 1999; (366): 91–97

    Article  PubMed  Google Scholar 

  39. Klyscz T., Rassner G., Guckenberger G., et al. Biomechanical stimulation therapy: a novel physiotherapy method for systemic sclerosis. Adv Exp Med Biol 1999; 455: 309–316

    Article  PubMed  CAS  Google Scholar 

  40. Jones N.F., Imbriglia J.E., Steen V.D., et al. Surgery for scleroderma of the hand. J Hand Surg [Am] 1987; 12 (3): 391–400

    CAS  Google Scholar 

  41. Anaya J.M., Talal N. Sjogren’s syndrome comes of age. Semin Arthritis Rheum 1999; 28 (6): 355–359

    Article  PubMed  CAS  Google Scholar 

  42. Premji S.S., Paes B. Cisapride: the problem of the heart. Neonatal Netw 1999; 18 (7): 21–25

    Article  PubMed  CAS  Google Scholar 

  43. Tonini M., De Ponti F, Di Nucci A, et al. Review article: cardiac adverse effects of gastrointestinal prokinetics. Aliment Pharmacol Ther 1999; 13 (12): 1585–1591

    Article  PubMed  CAS  Google Scholar 

  44. Ponec R.J., Saunders M.D., Kimmey M.B. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med 1999 Jul 15; 341 (3): 137–141

    Article  PubMed  CAS  Google Scholar 

  45. Steen V.D., Medsger Jr T.A. Epidemiology and natural history of systemic sclerosis. Rheum Dis Clin North Am 1990; 16 (1): 1–10

    PubMed  CAS  Google Scholar 

  46. Steen V.D., Conte C., Owens G.R., et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37 (9): 1283–1289

    Article  PubMed  CAS  Google Scholar 

  47. Steen V.D., Graham G., Conte C., et al. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 35 (7): 765–770

    Article  PubMed  CAS  Google Scholar 

  48. Steen V.D., Lanz Jr J.K., Conte C., et al. Therapy for severe interstitial lung disease in systemic sclerosis: a retrospective study. Arthritis Rheum 1994; 37 (9): 1290–1296

    Article  PubMed  CAS  Google Scholar 

  49. Davas E.M., Peppas C., Maragou M., et al. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999; 18 (6): 455–461

    Article  PubMed  CAS  Google Scholar 

  50. Akesson A., Scheja A., Lundin A., et al. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994; 37 (5): 729–735

    Article  PubMed  CAS  Google Scholar 

  51. Behr J., Vogelmeier C., Beinert T., et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996; 154 (2 Pt 1): 400–406

    PubMed  CAS  Google Scholar 

  52. Raghu G., Johnson W.C., Lockhart D., et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999; 159 (4 Pt 1): 1061–1069

    PubMed  CAS  Google Scholar 

  53. Stupi A.M., Steen V.D., Owens G.R., et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29 (4): 515–524

    Article  PubMed  CAS  Google Scholar 

  54. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med 1996 Feb 1; 334 (5): 296–302

    Article  PubMed  CAS  Google Scholar 

  55. Steen V.D., Costantino J.P., Shapiro A.P., et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990 Sep 1; 113 (5): 352–357

    PubMed  CAS  Google Scholar 

  56. Furst D.E., Clements P.J., Hillis S., et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma: results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum 1989; 32 (5): 584–593

    Article  PubMed  CAS  Google Scholar 

  57. Casas J.A., Saway P.A., Villarreal I., et al. 5-Fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study. Ann Rheum Dis 1990; 49 (11): 926–928

    Article  PubMed  CAS  Google Scholar 

  58. Furst D.E., Clements P.J., Steen V.D., et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998; 25 (1): 84–88

    PubMed  CAS  Google Scholar 

  59. Clements P.J., Lachenbruch P.A., Seibold J.R., et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20 (11): 1892–1896

    PubMed  CAS  Google Scholar 

  60. Steen V.D., Medsger Jr T.A., Rodnan G.P. D-penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982; 97 (5): 652–659

    PubMed  CAS  Google Scholar 

  61. Jimenez S.A., Sigal H.A. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J Rheumatol 1991; 18: 1435–1437

    Google Scholar 

  62. van den Hoogen F.H., Boerbooms A.M., Swaak A.J., et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35 (4): 364–372

    Article  PubMed  Google Scholar 

  63. Pope J., Bellamy N., Seibold J., et al. A randomized controlled trial of methotrexate (MTX) versus placebo in early diffuse scleroderma — a preliminary analysis [abstract]. Arthritis Rheum 1998 Nov 1; 41 Suppl. 9: S102

    Google Scholar 

  64. Dau P.C., Callahan J.P. Immune modulation during treatment of systemic sclerosis with plasmapheresis and immunosuppressive drugs. Clin Immunol Immunopathol 1994; 70 (2): 159–165

    Article  PubMed  CAS  Google Scholar 

  65. Rook A.H., Freundlich B., Nahass G.T., et al. Treatment of autoimmune disease with extracorporeal photochemotherapy: progressive systemic sclerosis. Yale J Biol Med 1989; 62 (6): 639–645

    PubMed  CAS  Google Scholar 

  66. Rook A.H., Freundlich B., Jegasothy B.V., et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy: results of a multicenter trial. Arch Dermatol 1992; 128 (3): 337–346

    Article  PubMed  CAS  Google Scholar 

  67. Rook A.H. Photopheresis in the treatment of autoimmune disease: experience with pemphigus vulgaris and systemic sclerosis. Ann N Y Acad Sci 1991 Dec 30; 636: 209–216

    Article  PubMed  CAS  Google Scholar 

  68. Wollina U., Oelzner S., Looks A., et al. Progressive systemic sclerosis — treatment results of extracorporeal photopheresis. Hautarzt 1999; 50 (9): 637–642

    Article  PubMed  CAS  Google Scholar 

  69. Krasagakis K., Dippel E., Ramaker J., et al. Management of severe scleroderma with long-term extracorporeal photopheresis. Dermatology 1998; 196 (3): 309–315

    Article  PubMed  CAS  Google Scholar 

  70. Schwartz J., Gonzalez J., Palangio M., et al. Extracorporeal photochemotherapy in progressive systemic sclerosis: a follow-up study. Int J Dermatol 1997; 36 (5): 380–385

    Article  PubMed  CAS  Google Scholar 

  71. Enomoto D.N., Mekkes J.R., Bossuyt P.M., et al. Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J Am Acad Dermatol 1999; 41 (6): 915–922

    Article  PubMed  CAS  Google Scholar 

  72. Mayes M.D. Photopheresis and autoimmune diseases. Rheum Dis Clin North Am 2000; 26 (1): 75–81

    Article  PubMed  CAS  Google Scholar 

  73. Morison W.L. Psoralen UVA therapy for linear and generalized morphea. J Am Acad Dermatol 1997; 37 (4): 657–659

    Article  PubMed  CAS  Google Scholar 

  74. Kanekura T., Fukumaru S., Matsushita S., et al. Successful treatment of scleroderma with PUVA therapy. J Dermatol 1996; 23 (7): 455–459

    PubMed  CAS  Google Scholar 

  75. Hofer A., Soyer H.P. Oral psoralen-UV-A for systemic scleroderma [letter]. Arch Dermatol 1999; 135 (5): 603–604

    Article  PubMed  CAS  Google Scholar 

  76. Morita A., Sakakibara S., Sakakibara N., et al. Successful treatment of systemic sclerosis with topical PUVA. J Rheumatol 1995; 22 (12): 2361–2235

    PubMed  CAS  Google Scholar 

  77. Seibold J.R., Korn J.H., Simms R., et al. Recombinant human relaxin in the treatment of scleroderma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000 Jun 6; 132 (11): 871–879

    PubMed  CAS  Google Scholar 

  78. Gisslinger H., Burghuber O.C., Stacher G., et al. Efficacy of cyclosporin A in systemic sclerosis. Clin Exp Rheumatol 1991; 9 (4): 383–390

    PubMed  CAS  Google Scholar 

  79. Clements P.J., Lachenbruch P.A., Sterz M., et al. Cyclosporine in systemic sclerosis: results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 1993; 36 (1): 75–83

    Article  PubMed  CAS  Google Scholar 

  80. Denton C.P., Sweny P., Abdulla A., et al. Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol 1994; 33 (1): 90–92

    Article  PubMed  CAS  Google Scholar 

  81. Filaci G., Cutolo M., Scudeletti M., et al. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology (Oxford) 1999; 38 (10): 992–996

    Article  CAS  Google Scholar 

  82. Steen V.D. An open trial of FK-506 in the treatment of early diffuse scleroderma [abstract]. Arthritis Rheum 1998; 41 Suppl.: S103

    Google Scholar 

  83. Morton S.J., Powell R.J. Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology (Oxford) 2000; 39 (8): 865–869

    Article  CAS  Google Scholar 

  84. Rosenbloom J., Feldman G., Freundlich B., et al. Inhibition of excessive scleroderma fibroblast collagen production by recombinant gamma-interferon: association with a coordinate decrease in types I and III procollagen messenger RNA levels. Arthritis Rheum 1986; 29 (7): 851–856

    Article  PubMed  CAS  Google Scholar 

  85. Kahan A., Amor B., Menkes C.J., et al. Recombinant interferon-gamma in the treatment of systemic sclerosis. Am J Med 1989; 87 (3): 273–277

    Article  PubMed  CAS  Google Scholar 

  86. Freundlich B., Jimenez S.A., Steen V.D., et al. Treatment of systemic sclerosis with recombinant interferon-gamma: a phase I/II clinical trial. Arthritis Rheum 1992; 35 (10): 1134–1142

    Article  PubMed  CAS  Google Scholar 

  87. Polisson R.P., Gilkeson G.S., Pyun E.H., et al. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. J Rheumatol 1996; 23 (4): 654–658

    PubMed  CAS  Google Scholar 

  88. Hunzelmann N., Anders S., Fierlbeck G., et al. Systemic scleroderma: multicenter trial of 1 year of treatment with recombinant interferon gamma. Arch Dermatol 1997; 133 (5): 609–613

    Article  PubMed  CAS  Google Scholar 

  89. Vlachoyiannopoulos P.G., Tsifetaki N., Dimitriou I., et al. Safety and efficacy of recombinant gamma interferon in the treatment of systemic sclerosis. Ann Rheum Dis 1996; 55 (10): 761–768

    Article  PubMed  CAS  Google Scholar 

  90. Black C.M., Silman A.J., Herrick A.I., et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999; 42 (2): 299–305

    Article  PubMed  CAS  Google Scholar 

  91. Stirling D., Sherman M., Strauss S. Thalidomide: a surprising recovery. J Am Pharm Assoc(Wash) 1997; NS37 (3): 306–313

    CAS  Google Scholar 

  92. Oliver S., Moreira A., Kaplan G. Reduced fibrosis and normalization of skin structure in scleroderma patients treated with thalidomide [abstract]. Arthritis Rheum 1999 Jan 11; 42 Suppl. 9: S187

    Google Scholar 

  93. Postlethwaite A.E. Connective tissue metabolism including cytokines in scleroderma. Curr Opin Rheumatol 1993; 5 (6): 766–762

    Article  PubMed  CAS  Google Scholar 

  94. McKown K.M., Carbone L.D., Bustillo J., et al. Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. Arthritis Rheum 2000; 43 (5): 1054–1061

    Article  PubMed  CAS  Google Scholar 

  95. Le C.H., Morales A., Trentham D.E. Minocycline in early diffuse scleroderma [letter]. Lancet 1998; 352 (9142): 1755–1756

    Article  PubMed  CAS  Google Scholar 

  96. Sullivan K.M., Furst D.E. The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases. J Rheumatol Suppl 1997; 48: 1–4

    PubMed  CAS  Google Scholar 

  97. Furst D.E., McSweeney P.A., Nash R., et al. High-dose immunosuppressive therapy with autologous stem cell treansplantation for systemic sclerosis [abstract]. Arthritis Rheum 2000; 43: S392

    Google Scholar 

  98. Thiel A., Rosen O., Kimmig S., et al. Long term followup of the immune reconstitution after autologous stem cell transplantation for severe autoimmune diseases [abstract]. Arthritis Rheum 2000; 43 Suppl.: S255

    Article  Google Scholar 

  99. Clements P.J., Furst D.E. Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation. J Rheumatol Suppl 1997; 48: 85–88

    PubMed  CAS  Google Scholar 

  100. Humbert P., Dupond J.L., Agache P., et al. Treatment of scleroderma with oral 1,25-dihydroxyvitamin D3: evaluation of skin involvement using non-invasive techniques: results of an open prospective trial. Acta Derm Venereol 1993; 73 (6): 449–451

    PubMed  CAS  Google Scholar 

  101. Pines M., Nagler A. Halofuginone: a novel antifibrotic therapy. Gen Pharmacol 1998; 30 (4): 445–450

    Article  PubMed  CAS  Google Scholar 

  102. Nagler A., Pines M. Topical treatment of cutaneous chronic graft versus host disease with halofuginone: a novel inhibitor of collagen type I synthesis. Transplantation 1999 Dec 15; 68 (11): 1806–1809

    Article  PubMed  CAS  Google Scholar 

  103. Clements P.J., Furst D.E., Wong W.K., et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999; 42 (6): 1194–1203

    Article  PubMed  CAS  Google Scholar 

  104. Steen V. Treatment of systemic sclerosis. Curr Opin Rheumatol 1991; 3 (6): 979–985

    Article  PubMed  CAS  Google Scholar 

  105. Morita A., Kobayashi K., Isomura I., et al. Ultraviolet A1 (340-400 Nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol 2000; 43 (4): 670–674

    Article  PubMed  CAS  Google Scholar 

  106. Unemori E.N., Amento E.P. Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J Biol Chem 1990 Jun 25; 265 (18): 10681–5

    PubMed  CAS  Google Scholar 

  107. Celltech Group PLC. Celltech announces results of Connetics Corporation’s Connetics Relaxin phase II/III study. Available from URL: http://www.medeva.co.uk/-company_information/press_releases/celltech_gro.../091000htm [Accessed 2001 Aug 10]

  108. Yamamoto T., Takagawa S., Katayama I., et al. Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma. Clin Immunol 1999; 92 (1): 6–13

    Article  PubMed  CAS  Google Scholar 

  109. Mizutani H., Yoshida T., Nouchi N., et al. Topical tocoretinate improved hypertrophic scar, skin sclerosis in systemic sclerosis and morphea. J Dermatol 1999; 26 (1): 11–17

    PubMed  CAS  Google Scholar 

  110. Cunningham B.B., Landells I.D., Langman C., et al. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol 1998; 39 (2 Pt 1): 211–215

    Article  PubMed  CAS  Google Scholar 

  111. Mizushima Y., Hoshi K., Yanagawa A., et al. Topical application of superoxide dismutase cream. Drugs Exp Clin Res 1991; 17 (2): 127–131

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Georgetown University, Washington, DC, 20007, USA

    Virginia D. Steen

Authors
  1. Virginia D. Steen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Virginia D. Steen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steen, V.D. Treatment of Systemic Sclerosis. Am J Clin Dermatol 2, 315–325 (2001). https://doi.org/10.2165/00128071-200102050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200102050-00006

Keywords

Search

Navigation